-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Drug safety is a major issue related to the national economy and people's livelihood.
In order to strengthen drug quality supervision and ensure the safety of drug use by the public, in recent years, the country and even local governments have actively carried out supervision and inspection of drug production, operation, and use units
.
At the same time, drug quality announcements have also begun to be frequently disclosed
.
Recently, Shanxi Province, Jiangxi Province, and Guangdong Drug Administration have successively issued quality announcements
.
According to the announcement, 29 batches of products from 26 companies including Jilin Province Mintai Pharmaceutical Co.
, Ltd.
did not meet the requirements after inspection, including 7 batches of preparations and 22 batches of Chinese medicine decoction pieces (1 decoction piece company had 2 batches denied production).
non-compliance projects include traits, water, microscopic identification, weight difference, aflatoxin and so on
.
Specifically, on November 9th, the Shanxi Provincial Drug Administration issued an announcement on the information of the first phase of drug random inspections in 2021
.
The announcement stated that a total of 1,408 batches of drugs were randomly inspected in Shanxi Province recently.
After verification, 1406 batches of drugs that met the standards were tested and 2 batches of drugs that did not meet the standards were tested
.
The two batches of products are safflower and baiziren, and the unqualified items are moisture and aflatoxin respectively
.
On November 10, the Guangdong Provincial Food and Drug Administration issued the "Notice on Drug Sampling Inspection Information (No.
9 in 2021)" notice
.
Among the 1821 batches of drugs inspected, 8 batches of drugs failed to pass the random inspection
.
It is worth noting that most of these unqualified products are Chinese herbal medicine pieces, namely Qinpi, rhubarb, kelp, dandelion, hemp pill, bran-fried atractylodes, and amomum
.
On the same day, the Food and Drug Administration of Guangdong Province also issued a notice on drug sampling inspection information.
The notice showed that 1813 batches of 911 varieties in Guangdong Province were tested and met the drug standards
.
In addition, 47 batches of 39 varieties did not meet the requirements
.
According to the unqualified drugs, most of them are Chinese medicine decoction pieces
.
The industry analysis believes that in recent years, the market supervision departments in various places have been constantly "strikes out", strengthened the special rectification of traditional Chinese medicine decoction pieces, and improved the quality of traditional Chinese medicine decoction pieces. .
However, the problems of Chinese herbal medicines reported from various places continue to occur, and even some large-scale Chinese medicine companies have problems
.
There is still a long way to go to ensure the safety of Chinese herbal medicines .
But in general, the development space of the traditional Chinese medicine decoction pieces market is becoming wider and wider, and the market size is expected to continue to expand in the future
.
In this context, pharmaceutical companies must further promote the development of the traditional Chinese medicine decoction pieces industry in a high-quality direction in order to better ensure the healthy development of the entire industry
.
In this regard, the industry has proposed that, first of all, all pharmaceutical companies need to further strengthen self-discipline, and strictly follow the requirements of the new version of the pharmacopoeia to do a good job in every link of planting, production, processing, and circulation
.
In addition, the problem of pesticide residues in decoction pieces of traditional Chinese medicine has always been a core pain point in the industry, and it is also a key difficulty to be solved by the 2020 Chinese Pharmacopoeia
.
Therefore, for manufacturers, it is necessary to continuously strengthen the independent inspection and testing capabilities of Chinese herbal medicines, and to train relevant high-quality professional inspection personnel so that they can operate the testing equipment more proficiently.
While ensuring the scientific and accurate testing results, Further ensure the quality and safety of Chinese herbal medicine pieces
.
In order to strengthen drug quality supervision and ensure the safety of drug use by the public, in recent years, the country and even local governments have actively carried out supervision and inspection of drug production, operation, and use units
.
At the same time, drug quality announcements have also begun to be frequently disclosed
.
Recently, Shanxi Province, Jiangxi Province, and Guangdong Drug Administration have successively issued quality announcements
.
According to the announcement, 29 batches of products from 26 companies including Jilin Province Mintai Pharmaceutical Co.
, Ltd.
did not meet the requirements after inspection, including 7 batches of preparations and 22 batches of Chinese medicine decoction pieces (1 decoction piece company had 2 batches denied production).
non-compliance projects include traits, water, microscopic identification, weight difference, aflatoxin and so on
.
Specifically, on November 9th, the Shanxi Provincial Drug Administration issued an announcement on the information of the first phase of drug random inspections in 2021
.
The announcement stated that a total of 1,408 batches of drugs were randomly inspected in Shanxi Province recently.
After verification, 1406 batches of drugs that met the standards were tested and 2 batches of drugs that did not meet the standards were tested
.
The two batches of products are safflower and baiziren, and the unqualified items are moisture and aflatoxin respectively
.
On November 10, the Guangdong Provincial Food and Drug Administration issued the "Notice on Drug Sampling Inspection Information (No.
9 in 2021)" notice
.
Among the 1821 batches of drugs inspected, 8 batches of drugs failed to pass the random inspection
.
It is worth noting that most of these unqualified products are Chinese herbal medicine pieces, namely Qinpi, rhubarb, kelp, dandelion, hemp pill, bran-fried atractylodes, and amomum
.
On the same day, the Food and Drug Administration of Guangdong Province also issued a notice on drug sampling inspection information.
The notice showed that 1813 batches of 911 varieties in Guangdong Province were tested and met the drug standards
.
In addition, 47 batches of 39 varieties did not meet the requirements
.
According to the unqualified drugs, most of them are Chinese medicine decoction pieces
.
The industry analysis believes that in recent years, the market supervision departments in various places have been constantly "strikes out", strengthened the special rectification of traditional Chinese medicine decoction pieces, and improved the quality of traditional Chinese medicine decoction pieces. .
However, the problems of Chinese herbal medicines reported from various places continue to occur, and even some large-scale Chinese medicine companies have problems
.
There is still a long way to go to ensure the safety of Chinese herbal medicines .
But in general, the development space of the traditional Chinese medicine decoction pieces market is becoming wider and wider, and the market size is expected to continue to expand in the future
.
In this context, pharmaceutical companies must further promote the development of the traditional Chinese medicine decoction pieces industry in a high-quality direction in order to better ensure the healthy development of the entire industry
.
In this regard, the industry has proposed that, first of all, all pharmaceutical companies need to further strengthen self-discipline, and strictly follow the requirements of the new version of the pharmacopoeia to do a good job in every link of planting, production, processing, and circulation
.
In addition, the problem of pesticide residues in decoction pieces of traditional Chinese medicine has always been a core pain point in the industry, and it is also a key difficulty to be solved by the 2020 Chinese Pharmacopoeia
.
Therefore, for manufacturers, it is necessary to continuously strengthen the independent inspection and testing capabilities of Chinese herbal medicines, and to train relevant high-quality professional inspection personnel so that they can operate the testing equipment more proficiently.
While ensuring the scientific and accurate testing results, Further ensure the quality and safety of Chinese herbal medicine pieces
.
